Merck's Q3 2018 earnings call highlights strong performance, particularly in KEYTRUDA, which continues to dominate the oncology market.  Management expressed confidence in the long-term outlook and executed a dividend increase and accelerated share repurchase program, showcasing a commitment to shareholder returns while maintaining investment in research and development.  Significant growth in vaccines and animal health also underscores a diversified and robust business model.
[2]
